Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 19/20 | 0.89 |
| ▸ | INSR | P06213 | 16/20 | 0.89 |
| ▸ | PTK2 | Q05397 | 12/20 | 0.89 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.66 |
| ▸ | MET | P08581 | 2/20 | 0.60 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.59 |
| ▸ | IGF1R | P08069 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cep-37440 SCHEMBL29489150 | 0.94 | ALK (1.00) | ALKINSRPTK2KCNH2MET | |
| Cep-37440 SCHEMBL15272087 | 0.94 | ALK (1.00) | ALKINSRPTK2KCNH2MET | |
| Cep-37440 SCHEMBL16571623 | 0.94 | ALK (1.00) | ALKINSRPTK2KCNH2MET | |
| Cep-37440 SCHEMBL31579317 | 0.94 | ALK (1.00) | ALKINSRPTK2KCNH2MET | |
| Cep-37440 SCHEMBL29354193 | 0.94 | ALK (1.00) | ALKINSRPTK2KCNH2MET | |
| Cep-37440 SCHEMBL15269443 | 0.94 | ALK (1.00) | ALKINSRPTK2KCNH2MET | |
| SCHEMBL16570664 | 0.94 | ALK (0.83) | ALKINSRPTK2KCNH2MET | |
| Cep-37440 SCHEMBL15269779 | 0.93 | ALK (0.99) | ALKINSRPTK2KCNH2MET | |
| SCHEMBL16571176 | 0.93 | ALK (0.91) | ALKINSRPTK2KCNH2MET | |
| SCHEMBL23810091 | 0.93 | ALK (0.82) | ALKINSRPTK2KCNH2MET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019113071-A1 | COMPOSITIONS AND METHODS FOR TREATING ALK-MEDIATED CANCER | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2019-06-13 | — | — | WO | disclosed |